Clinical Trial Update: Imaging Study of [89Zr]DFO-YS5 for Detecting CD46 Positive Malignancy in Multiple Myeloma [Phase 1]

View source ↗

Summary

Phase 1 clinical trial evaluating an imaging agent, 89Zr-DFO-YS5, for detecting CD46-positive malignancies in multiple myeloma. The study is currently recruitin…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• 89Zr-DFO-YS5

Snippet

Sponsor: Robert Flavell, MD, PhD | Conditions: Multiple Myeloma, Plasma Cell Myeloma | Phase 1 | Status: RECRUITING